Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

EIK1005-002: Un estudio de investigación clínica que evalúa EIK1005, un inhibidor de la helicasa de Werner, como monoterapia y en combinación con pembrolizumab en participantes con tumores sólidos avanzados, incluidos tumores con inestabilidad de microsatélites alta (MSI-H)

29 de octubre de 2026 actualizado por: Eikon Therapeutics

Un estudio multicéntrico, de múltiples partes, de fase 1/2 de EIK1005 como monoterapia y en combinación con pembrolizumab en participantes con tumores sólidos avanzados, incluidos participantes sin exposición previa a inhibidores de puntos de control con tumores con inestabilidad de microsatélites alta (MSI-H) o deficiencia en la reparación de errores de emparejamiento (dMMR)

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Descripción general del estudio

Descripción detallada

This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.

The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:

  • Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
  • Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
  • Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

160

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Ana C Mamede, PharmD
  • Número de teléfono: 347-806-4584
  • Correo electrónico: mamedea@eikontx.com

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Berlin, Alemania, 13125
        • Reclutamiento
        • Helios Klinikum Berlin-Buch
      • Hamburg, Alemania, 22297
        • Reclutamiento
        • Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
    • Bavaria
      • Deggendorf, Bavaria, Alemania, 94469
        • Reclutamiento
        • DONAUISAR Klinikum
    • New South Wales
      • Saint Leonards, New South Wales, Australia
        • Aún no reclutando
        • GenesisCare North Shore (Oncology)
      • Waratah, New South Wales, Australia
        • Reclutamiento
        • Calvary Mater Newcastle Hospital
    • Victoria
      • Ballarat, Victoria, Australia
        • Reclutamiento
        • Grampians Health
      • Camperdown, Victoria, Australia
        • Reclutamiento
        • Chris O'Brien Lifehouse (Sydney Cancer Centre)
      • Frankston, Victoria, Australia
        • Reclutamiento
        • Peninsula and Southeast Oncology (PASO) Medical
      • Frankston, Victoria, Australia, 3199
        • Reclutamiento
        • Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
      • Linz, Austria, 4020
        • Reclutamiento
        • Ordensklinikum Linz Elisabethinen
      • Brussels, Bélgica, 1020
        • Reclutamiento
        • Centre Hospitalier Universitaire Brugmann - Victor Horta
      • Seoul, Corea del Sur, 02841
        • Reclutamiento
        • Korea University Anam Hospital
      • Suwon, Corea del Sur, 16499
        • Reclutamiento
        • Ajou University School of Medicine & Graduate School of Medicine
    • Busan
      • Busan, Busan, Corea del Sur, 48108
        • Reclutamiento
        • Inje University-Haeundae Paik Hospital
      • Barcelona, España, 08023
        • Reclutamiento
        • START - Barcelona
      • Logroño, España, 26006
        • Reclutamiento
        • START Rioja - Hospital de San Pedro
      • Madrid, España, 28233
        • Reclutamiento
        • NEXT Madrid HUQSM
      • Zaragoza, España, 50009
        • Reclutamiento
        • Hospital Universitario Miguel Servet
    • Balearic Islands
      • Palma, Balearic Islands, España, 07120
        • Reclutamiento
        • Hospital Universitari Son Espases
    • Barcelona
      • Barcelona, Barcelona, España, 8036
        • Reclutamiento
        • Hospital Clinic Barcelona
    • California
      • Los Angeles, California, Estados Unidos, 90027
        • Reclutamiento
        • California Research Institute (CRI)
    • Florida
      • Doral, Florida, Estados Unidos, 33172
        • Reclutamiento
        • Omnicure Clinical Research
      • Hialeah, Florida, Estados Unidos, 33013
        • Reclutamiento
        • Bioresearch Partner
      • Plantation, Florida, Estados Unidos, 33322
        • Reclutamiento
        • Florida Clinical Trials Group
      • Tamarac, Florida, Estados Unidos, 33321
        • Reclutamiento
        • Florida Clinical Trials Group - Tamarac
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07960
        • Reclutamiento
        • Morristown Medical Center
    • New York
      • Lake Success, New York, Estados Unidos, 11042
        • Reclutamiento
        • START New York-Long Island
      • New York, New York, Estados Unidos, 10022
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center (MSKCC)
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Reclutamiento
        • START Dallas Fort Worth
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • University of Texas MD Anderson Cancer Center
      • Kuopio, Finlandia, 70210
        • Reclutamiento
        • Kuopio University Hospital
    • Rhone
      • Pierre-Bénite, Rhone, Francia, 69310
        • Reclutamiento
        • Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
      • Rome, Italia, 00128
        • Reclutamiento
        • Campus Bio-Medico di Rome University
      • Oslo, Noruega, 0379
        • Reclutamiento
        • Oslo University
      • Wellington, Nueva Zelanda
        • Reclutamiento
        • Health New Zealand
    • Manawatu
      • Roslyn, Manawatu, Nueva Zelanda, 4414
        • Reclutamiento
        • Palmerstone North Hospital
      • Krakow, Polonia, 31-864
        • Reclutamiento
        • GCPMED Sp. z o.o., Centrum Medyczne iMed24
      • Lodz, Polonia, 90-338
        • Reclutamiento
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polonia, 70-419
        • Reclutamiento
        • One Day Med
      • Lisbon, Portugal, 1649-028
        • Reclutamiento
        • Hospital de Santa Maria
      • Loures, Portugal, 2674-514
        • Reclutamiento
        • Unidade Local de Saúde (ULS) Loures Odivelas
      • Porto, Portugal, 4200
        • Reclutamiento
        • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1500-650
        • Reclutamiento
        • Hospital da Luz Lisboa
      • Singapore, Singapur, 119074
        • Reclutamiento
        • National University Hospital (NUH)
    • Central Region
      • Singapore, Central Region, Singapur, 168583
        • Reclutamiento
        • National Cancer Centre Singapore (NCCS)

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

  1. is ≥ 18 years of age at the time of signing the informed consent.
  2. has a life expectancy of at least 3 months.
  3. has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
  4. In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
  5. has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
  6. has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
  7. has an adequate organ and marrow function.

Key Exclusion Criteria:

  1. has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
  2. has received prior treatment with Werner (WRN) inhibitor.
  3. has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
  4. In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
  5. has known additional malignancy that is progressing or has required active treatment within the past 3 years.
  6. has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
  7. has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
  8. has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
  9. has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
  10. has active tuberculosis.
  11. has any active infections requiring systemic therapy.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part 1A (Dose escalation, Monotherapy)

EIK1005 will be given as monotherapy in participants without alternative treatment options.

EIK1005 is a selective inhibitor of the Werner helicase.

Experimental: Part 1B (Dose escalation, Combination with pembrolizumab)

EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors.

EIK1005 is a selective inhibitor of the Werner helicase.

Pembrolizumab is a PD-1 inhibitor.

Experimental: Part 2 (Dose optimization, Monotherapy)

Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A.

EIK1005 is a selective inhibitor of the Werner helicase.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Dose-Limiting Toxicity (DLT) - Part 1
Periodo de tiempo: 21 Days

A DLT is a protocol-defined adverse event occurring during the DLT observation period.

21 Days
Adverse Events (AEs) - Part 1 and Part 2
Periodo de tiempo: From the time of first dose of study medication through 30 days following cessation of study treatment.

Number of participants reporting adverse events or serious adverse events.

From the time of first dose of study medication through 30 days following cessation of study treatment.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response (OR) - Part 1 and Part 2
Periodo de tiempo: Through study completion, an average of 2 years.

OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Duration of Response (DOR) - Part 1 and Part 2
Periodo de tiempo: Through study completion, an average of 2 years.

DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Disease Control (DC) - Part 1 and Part 2
Periodo de tiempo: Through study completion, an average of 2 years.

DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Progression-free survival (PFS) - Part 2
Periodo de tiempo: Through study completion, an average of 2 years.

PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first.

Through study completion, an average of 2 years.
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Periodo de tiempo: Up to 1 year

AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Periodo de tiempo: Up to 1 year

AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Periodo de tiempo: Up to 1 year

Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Periodo de tiempo: Up to 1 year

tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Periodo de tiempo: Up to 1 year

Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Director de estudio: Nilou Mobashery, MD, Eikon Therapeutics, Inc.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de enero de 2026

Finalización primaria (Estimado)

1 de marzo de 2029

Finalización del estudio (Estimado)

1 de marzo de 2029

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

1 de diciembre de 2025

Publicado por primera vez (Actual)

3 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de octubre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir